Harald C. Ott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Harald C. Ott has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Jacques P. Guyette
Center for Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts
5 shared publications- Sarah Elizabeth Gilpin
Massachusetts General Hospital, Harvard Medical School, Boston, United States of America
4 shared publications - Bernhard J. Jank
Department of Otorhinolaryngology, Head and Neck Surgery Medical University of Vienna Vienna Austria
3 shared publications - Gabriel Gonzalez
Division of Genetics, Brigham and Women’s Hospital, Boston, MA, USA
3 shared publications Philipp T. Moser
3 shared publicationsCurtis L. Cetrulo
Divison of Plastic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts
2 shared publications
Latest Publications
- 29 September 2021
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 275 (2) , e537-E537
Invited Commentary: “Robotic Airway Resection Under Spontaneous Ventilation”
An abstract is unavailable. This article is available as a PDF only.
- 29 September 2021
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 275 (2) , e537-E537
Invited Commentary: “Robotic Airway Resection Under Spontaneous Ventilation”
An abstract is unavailable. This article is available as a PDF only.
- 2 October 2018
- Published by Springer Nature in Current Diabetes Reports
- Vol. 18 (11) , 1-7
Can We Re-Engineer the Endocrine Pancreas?
Purpose of Review Engineering endocrine pancreatic tissue is an emerging topic in type 1 diabetes with the intent to overcome the current limitation of β cell transplantation. During islet isolation, the vascularized structure and surrounding extracellular matrix (ECM) are completely disrupted. Once implanted, islets slowly engraft and mostly are lost for the initial avascular phase. This review discusses the main building blocks required to engineer the endocrine pancreas: (i) islet niche ECM, (ii) islet niche vascular network, and (iii) new available sources of endocrine cells. Recent Findings Current approaches include the following: tissue engineering of endocrine grafts by seeding of native or synthetic ECM scaffolds with human islets, vascularization of native or synthetic ECM prior to implantation, vascular functionalization of ECM structures to enhance angiogenesis after implantation, generation of engineered animals as human organ donors, and embryonic and pluripotent stem cell-derived endocrine cells that may be encapsulated or genetically engineered to be immunotolerated. Summary Substantial technological improvements have been made to regenerate or engineer endocrine pancreatic tissue; however, significant hurdles remain, and more research is needed to develop a technology to integrate all components of viable endocrine tissue for clinical application.
- 2 October 2018
- Published by Springer Nature in Current Diabetes Reports
- Vol. 18 (11) , 1-7
Can We Re-Engineer the Endocrine Pancreas?
Purpose of Review Engineering endocrine pancreatic tissue is an emerging topic in type 1 diabetes with the intent to overcome the current limitation of β cell transplantation. During islet isolation, the vascularized structure and surrounding extracellular matrix (ECM) are completely disrupted. Once implanted, islets slowly engraft and mostly are lost for the initial avascular phase. This review discusses the main building blocks required to engineer the endocrine pancreas: (i) islet niche ECM, (ii) islet niche vascular network, and (iii) new available sources of endocrine cells. Recent Findings Current approaches include the following: tissue engineering of endocrine grafts by seeding of native or synthetic ECM scaffolds with human islets, vascularization of native or synthetic ECM prior to implantation, vascular functionalization of ECM structures to enhance angiogenesis after implantation, generation of engineered animals as human organ donors, and embryonic and pluripotent stem cell-derived endocrine cells that may be encapsulated or genetically engineered to be immunotolerated. Summary Substantial technological improvements have been made to regenerate or engineer endocrine pancreatic tissue; however, significant hurdles remain, and more research is needed to develop a technology to integrate all components of viable endocrine tissue for clinical application.
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 225 (4) , S197
Robotic Resection of Small Pulmonary Nodules after Image-Guided Marker Placement
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 225 (4) , S197
Robotic Resection of Small Pulmonary Nodules after Image-Guided Marker Placement
- 1 July 2017
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 23 (13-14) , 696-707
Creation of a Bioengineered Skin Flap Scaffold with a Perfusable Vascular Pedicle
Full-thickness skin loss is a challenging problem due to limited reconstructive options, demanding 75 million surgical procedures annually in the United States. Autologous skin grafting is the gold standard treatment, but results in donor-site morbidity and poor aesthetics. Numerous skin substitutes are available on the market to date, however, none truly functions as full-thickness skin due to lack of a vascular network. The creation of an autologous full-thickness skin analogue with a vascular pedicle would result in a paradigm shift in the management of wounds and in reconstruction of full-thickness skin defects. To create a clinically relevant foundation, we generated an acellular skin flap scaffold (SFS) with a perfusable vascular pedicle of clinically relevant size by perfusion decellularization of porcine fasciocutaneous flaps. We then analyzed the yielded SFS for mechanical properties, biocompatibility, and regenerative potential in vitro and in vivo. Furthermore, we assessed the immunological response using an in vivo model. Finally, we recellularized the vascular compartment of an SFS and reconnected it to a recipient's blood supply to test for perfusability. Perfusion decellularization removed all cellular components with preservation of native extracellular matrix composition and architecture. Biaxial testing revealed preserved mechanical properties. Immunologic response and biocompatibility assessed via implantation and compared with native xenogenic skin and commercially available dermal substitutes revealed rapid neovascularization and complete tissue integration. Composition of infiltrating immune cells showed no evidence of allorejection and resembled the inflammatory phase of wound healing. Implantation into full-thickness skin defects demonstrated good tissue integration and skin regeneration without cicatrization. We have developed a protocol for the generation of an SFS of clinically relevant size, containing a vascular pedicle, which can be utilized for perfusion decellularization and, ultimately, anastomosis to the recipient vascular system after precellularization. The observed favorable immunological response and good tissue integration indicate the substantial regenerative potential of this platform.
- 1 July 2017
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 23 (13-14) , 696-707
Creation of a Bioengineered Skin Flap Scaffold with a Perfusable Vascular Pedicle
Full-thickness skin loss is a challenging problem due to limited reconstructive options, demanding 75 million surgical procedures annually in the United States. Autologous skin grafting is the gold standard treatment, but results in donor-site morbidity and poor aesthetics. Numerous skin substitutes are available on the market to date, however, none truly functions as full-thickness skin due to lack of a vascular network. The creation of an autologous full-thickness skin analogue with a vascular pedicle would result in a paradigm shift in the management of wounds and in reconstruction of full-thickness skin defects. To create a clinically relevant foundation, we generated an acellular skin flap scaffold (SFS) with a perfusable vascular pedicle of clinically relevant size by perfusion decellularization of porcine fasciocutaneous flaps. We then analyzed the yielded SFS for mechanical properties, biocompatibility, and regenerative potential in vitro and in vivo. Furthermore, we assessed the immunological response using an in vivo model. Finally, we recellularized the vascular compartment of an SFS and reconnected it to a recipient's blood supply to test for perfusability. Perfusion decellularization removed all cellular components with preservation of native extracellular matrix composition and architecture. Biaxial testing revealed preserved mechanical properties. Immunologic response and biocompatibility assessed via implantation and compared with native xenogenic skin and commercially available dermal substitutes revealed rapid neovascularization and complete tissue integration. Composition of infiltrating immune cells showed no evidence of allorejection and resembled the inflammatory phase of wound healing. Implantation into full-thickness skin defects demonstrated good tissue integration and skin regeneration without cicatrization. We have developed a protocol for the generation of an SFS of clinically relevant size, containing a vascular pedicle, which can be utilized for perfusion decellularization and, ultimately, anastomosis to the recipient vascular system after precellularization. The observed favorable immunological response and good tissue integration indicate the substantial regenerative potential of this platform.
- 8 January 2016
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 118 (1) , 56-72
Bioengineering Human Myocardium on Native Extracellular Matrix
Rationale:: More than 25 million individuals have heart failure worldwide, with ≈4000 patients currently awaiting heart transplantation in the United States. Donor organ shortage and allograft rejection remain major limitations with only ≈2500 hearts transplanted each year. As a theoretical alternative to allotransplantation, patient-derived bioartificial myocardium could provide functional support and ultimately impact the treatment of heart failure. Objective:: The objective of this study is to translate previous work to human scale and clinically relevant cells for the bioengineering of functional myocardial tissue based on the combination of human cardiac matrix and human induced pluripotent stem cell–derived cardiomyocytes. Methods and Results:: To provide a clinically relevant tissue scaffold, we translated perfusion-decellularization to human scale and obtained biocompatible human acellular cardiac scaffolds with preserved extracellular matrix composition, architecture, and perfusable coronary vasculature. We then repopulated this native human cardiac matrix with cardiomyocytes derived from nontransgenic human induced pluripotent stem cells and generated tissues of increasing 3-dimensional complexity. We maintained such cardiac tissue constructs in culture for 120 days to demonstrate definitive sarcomeric structure, cell and matrix deformation, contractile force, and electrical conduction. To show that functional myocardial tissue of human scale can be built on this platform, we then partially recellularized human whole-heart scaffolds with human induced pluripotent stem cell–derived cardiomyocytes. Under biomimetic culture, the seeded constructs developed force-generating human myocardial tissue and showed electrical conductivity, left ventricular pressure development, and metabolic function. Conclusions:: Native cardiac extracellular matrix scaffolds maintain matrix components and structure to support the seeding and engraftment of human induced pluripotent stem cell–derived cardiomyocytes and enable the bioengineering of functional human myocardial-like tissue of multiple complexities.
- 8 January 2016
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 118 (1) , 56-72
Bioengineering Human Myocardium on Native Extracellular Matrix
Rationale:: More than 25 million individuals have heart failure worldwide, with ≈4000 patients currently awaiting heart transplantation in the United States. Donor organ shortage and allograft rejection remain major limitations with only ≈2500 hearts transplanted each year. As a theoretical alternative to allotransplantation, patient-derived bioartificial myocardium could provide functional support and ultimately impact the treatment of heart failure. Objective:: The objective of this study is to translate previous work to human scale and clinically relevant cells for the bioengineering of functional myocardial tissue based on the combination of human cardiac matrix and human induced pluripotent stem cell–derived cardiomyocytes. Methods and Results:: To provide a clinically relevant tissue scaffold, we translated perfusion-decellularization to human scale and obtained biocompatible human acellular cardiac scaffolds with preserved extracellular matrix composition, architecture, and perfusable coronary vasculature. We then repopulated this native human cardiac matrix with cardiomyocytes derived from nontransgenic human induced pluripotent stem cells and generated tissues of increasing 3-dimensional complexity. We maintained such cardiac tissue constructs in culture for 120 days to demonstrate definitive sarcomeric structure, cell and matrix deformation, contractile force, and electrical conduction. To show that functional myocardial tissue of human scale can be built on this platform, we then partially recellularized human whole-heart scaffolds with human induced pluripotent stem cell–derived cardiomyocytes. Under biomimetic culture, the seeded constructs developed force-generating human myocardial tissue and showed electrical conductivity, left ventricular pressure development, and metabolic function. Conclusions:: Native cardiac extracellular matrix scaffolds maintain matrix components and structure to support the seeding and engraftment of human induced pluripotent stem cell–derived cardiomyocytes and enable the bioengineering of functional human myocardial-like tissue of multiple complexities.
- 1 September 2015
- Published by Wolters Kluwer Health in Transplantation
- Vol. 99 (9) , 1753
Perfusion Decellularization of Discarded Human Kidneys
- 1 September 2015
- Published by Wolters Kluwer Health in Transplantation
- Vol. 99 (9) , 1753
Perfusion Decellularization of Discarded Human Kidneys
- 1 August 2015
- Published by Elsevier in Biomaterials
- Vol. 61, 246-256
Engineered composite tissue as a bioartificial limb graft
- 1 August 2015
- Published by Elsevier in Biomaterials
- Vol. 61, 246-256
Engineered composite tissue as a bioartificial limb graft
- 1 November 2014
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 98 (5) , 1721-1729
Enhanced Lung Epithelial Specification of Human Induced Pluripotent Stem Cells on Decellularized Lung Matrix
- 1 November 2014
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 98 (5) , 1721-1729
Enhanced Lung Epithelial Specification of Human Induced Pluripotent Stem Cells on Decellularized Lung Matrix
- 1 March 2014
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 33 (3) , 298-308
Perfusion decellularization of human and porcine lungs: Bringing the matrix to clinical scale
- 1 March 2014
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 33 (3) , 298-308
Perfusion decellularization of human and porcine lungs: Bringing the matrix to clinical scale
- 30 September 2013
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 96 (3) , 1056
Invited Commentary
- 30 September 2013
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 96 (3) , 1056
Invited Commentary